Worth Asset Management LLC Has $1.76 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Worth Asset Management LLC cut its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 1.9% during the 2nd quarter, Holdings Channel reports. The firm owned 9,897 shares of the company’s stock after selling 188 shares during the quarter. Johnson & Johnson makes up approximately 1.2% of Worth Asset Management LLC’s holdings, making the stock its 15th largest holding. Worth Asset Management LLC’s holdings in Johnson & Johnson were worth $1,757,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in JNJ. Magnolia Capital Management Ltd. increased its holdings in Johnson & Johnson by 0.5% during the 1st quarter. Magnolia Capital Management Ltd. now owns 11,162 shares of the company’s stock worth $1,978,000 after acquiring an additional 55 shares during the period. Howard Financial Services LTD. increased its holdings in Johnson & Johnson by 2.1% during the 1st quarter. Howard Financial Services LTD. now owns 2,757 shares of the company’s stock worth $489,000 after acquiring an additional 57 shares during the period. American Financial Advisors LLC increased its holdings in Johnson & Johnson by 2.1% during the 1st quarter. American Financial Advisors LLC now owns 2,715 shares of the company’s stock worth $481,000 after acquiring an additional 57 shares during the period. Taylor & Morgan Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 1.6% in the 2nd quarter. Taylor & Morgan Wealth Management LLC now owns 3,580 shares of the company’s stock worth $635,000 after buying an additional 57 shares during the last quarter. Finally, Kwmg LLC increased its holdings in shares of Johnson & Johnson by 2.6% in the 1st quarter. Kwmg LLC now owns 2,354 shares of the company’s stock worth $417,000 after buying an additional 59 shares during the last quarter. 68.59% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Up 1.5 %

Shares of JNJ opened at $167.60 on Monday. The stock has a market capitalization of $440.65 billion, a P/E ratio of 24.40, a PEG ratio of 2.99 and a beta of 0.61. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt-to-equity ratio of 0.37. The firm has a fifty day simple moving average of $168.96 and a two-hundred day simple moving average of $174.29. Johnson & Johnson has a twelve month low of $155.72 and a twelve month high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.57 by $0.02. The business had revenue of $24.02 billion during the quarter, compared to analysts’ expectations of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.48 EPS. On average, research analysts anticipate that Johnson & Johnson will post 10.7 EPS for the current year.

Johnson & Johnson declared that its Board of Directors has approved a stock buyback program on Wednesday, September 14th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the company to purchase up to 1.2% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s management believes its shares are undervalued.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd were issued a $1.13 dividend. The ex-dividend date of this dividend was Monday, August 22nd. This represents a $4.52 annualized dividend and a yield of 2.70%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 65.79%.

Analyst Ratings Changes

JNJ has been the topic of a number of research analyst reports. Citigroup decreased their price target on shares of Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. SVB Leerink decreased their price target on shares of Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. UBS Group decreased their price target on shares of Johnson & Johnson from $185.00 to $180.00 in a report on Thursday, July 21st. Morgan Stanley decreased their price target on shares of Johnson & Johnson from $174.00 to $173.00 and set an “equal weight” rating on the stock in a report on Monday, September 12th. Finally, Wells Fargo & Company upped their price objective on shares of Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a research note on Wednesday, July 13th. Four analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $189.78.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.